Outset Medical
Outset Medical's revenue rose 5.1% to $120 million in fiscal 2025. Its operating margin was −55.8%, up from −99.7% a year earlier. Free cash flow was −$47 million. The diluted share count rose 339.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Outset Medical lost money in fiscal 2025: a net loss of $82 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 340 | 288 | 203 | 159 | 169 |
| Debt incl. finance leases | 30 | 96 | 130 | 197 | 96 |
| Net debt (negative means net cash) | −310 | −191 | −73 | 39 | −73 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.4x | 1.1x | 7.4x | 0.8x |
| Interest coverage | −76.1x | −45.1x | −13.4x | −4.8x | −4.8x |
| Current ratio | 7.9x | 7.2x | 5.3x | 5.7x | 6.7x |
| Quick ratio | 7.2x | 6.2x | 4.4x | 4.4x | 5.4x |
Cash flow
Projections
Project Outset Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Outset Medical shares on the open market, and 5 insiders sold $362,051.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Renee GaetaChief Financial Officer | Sold | 4,543 | $4.39 | $19,944 | Form 4 |
| Aug 17, 2026 | Leslie TriggChair and CEO, Director | Sold | 3,437 | $4.39 | $15,088 | Form 4 |
| Aug 17, 2026 | John L. BrottemGeneral Counsel | Sold | 2,632 | $4.39 | $11,554 | Form 4 |
| Jun 3, 2026 | Renee GaetaChief Financial Officer | Sold | 17,672 | $4.94 | $87,300 | Form 4 |
| May 15, 2026 | Leslie TriggChair and CEO, Director | Sold | 3,445 | $3.70 | $12,746 | Form 4 |
| May 15, 2026 | John L. BrottemGeneral Counsel | Sold | 2,638 | $3.70 | $9,761 | Form 4 |
| May 15, 2026 | Marc NashEVP Operations R&D & Service | Sold | 1,582 | $3.70 | $5,853 | Form 4 |
| Feb 17, 2026 | Leslie TriggChair and CEO, Director | Sold | 3,361 | $3.35 | $11,259 | Form 4 |
| Feb 17, 2026 | John L. BrottemGeneral Counsel | Sold | 2,842 | $3.35 | $9,521 | Form 4 |
| Feb 17, 2026 | Marc NashEVP Operations R&D & Service | Sold | 1,817 | $3.35 | $6,087 | Form 4 |
| Jan 21, 2026 | Leslie TriggChair and CEO, Director | Sold | 2,120 | $5.05 | $10,706 | Form 4 |
| Jan 21, 2026 | John L. BrottemGeneral Counsel | Sold | 1,180 | $5.01 | $5,912 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 5 of 9 | 6 of 9 |
| Rule of 40 | −90.4% | −115.9% | −34.4% |
| Altman Z'' | −8.02 | −10.47 | −9.87 |
| Accruals ratio | −11.6% | −4.0% | −13.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | 5 of 9 | 6 of 9 |
Compare
Put Outset Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Outset Medical | FY25 | 5.1% | −55.8% | −39.4% | −88.0% | — | 6 | |
| OraSure Technologies | FY25 | −38.1% | −62.6% | −46.3% | — | — | — | Compare |
| Anika Therapeutics | FY25 | −5.9% | −9.8% | 3.9% | — | — | — | Compare |
| Xtant Medical | FY25 | 14.2% | 5.4% | 7.6% | 10.0% | −0.5x | 8 | Compare |
| Owlet | FY25 | 35.4% | −7.8% | −10.5% | — | — | 5 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 2 | 15 | 50 | 103 | 115 | 130 | 114 | 120 |
| Revenue growth | — | 651.3% | 231.2% | 105.5% | 12.4% | 13.0% | −12.8% | 5.1% |
| Gross profit | −6 | −18 | −13 | 8 | 18 | 29 | 39 | 47 |
| Research and development | 23 | 23 | 29 | 37 | 49 | 57 | 38 | 21 |
| Operating income | −47 | −70 | −118 | −130 | −161 | −170 | −113 | −67 |
| Net income | −50 | −68 | −122 | −132 | −163 | −173 | −128 | −82 |
| Diluted EPS (US$) | −1,511.25 | −1,493.70 | −72.75 | −43.35 | −50.70 | −52.28 | −36.96 | −5.37 |
| Diluted shares (millions) | 0 | 0 | 0 | 3 | 3 | 3 | 4 | 15 |
| Cash flow | ||||||||
| Cash from operations | −46 | −70 | −99 | −130 | −146 | −131 | −116 | −46 |
| Capital expenditure | 2 | 3 | 9 | 3 | 8 | 3 | 1 | 1 |
| Free cash flow | −48 | −74 | −108 | −133 | −154 | −135 | −117 | −47 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 21 | 17 | 27 | 39 | 29 | 16 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | — | 70 | 315 | 340 | 288 | 203 | 159 | 169 |
| Debt incl. finance leases | — | 29 | 30 | 30 | 96 | 130 | 197 | 96 |
| Total assets | — | 88 | 404 | 464 | 400 | 314 | 276 | 264 |
| Total liabilities | — | 51 | 75 | 89 | 154 | 191 | 249 | 138 |
| Shareholders' equity | −288 | −372 | 329 | 374 | 246 | 123 | 27 | 127 |
| Margins and ratios | ||||||||
| Gross margin | −304.7% | −118.1% | −26.1% | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Operating margin | −2,320.0% | −466.3% | −235.2% | −127.2% | −139.6% | −130.2% | −99.7% | −55.8% |
| Net margin | −2,480.3% | −453.0% | −243.3% | −128.6% | −141.2% | −132.5% | −112.6% | −68.3% |
| Free cash flow margin | −2,402.0% | −488.0% | −216.5% | −130.0% | −133.5% | −103.4% | −103.1% | −39.4% |
| Rule of 40 (growth + FCF margin) | — | 163.2% | 14.7% | −24.5% | −121.1% | −90.4% | −115.9% | −34.4% |
| Return on capital | — | — | — | −191.4% | −213.5% | −256.7% | −155.5% | −88.0% |
| Return on equity | — | — | — | −37.5% | −52.6% | −93.7% | −171.0% | −106.2% |
| Return on assets | — | — | −49.4% | −30.4% | −37.7% | −48.4% | −43.4% | −30.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |